Skip to main content

Table 2 Prevalence of FibroTest with high-risk profile of false positive/negative (RFPN1)

From: Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age

Parameters All (P3) n = 345,695 Reference center (P4) n = 24,872
  Lower limit and
RFPN n (%)
Upper limit and
RFPN n (%)
Lower limit and
RFPN n (%)
Upper limit and
RFPN n (%)
Haptoglobin g/L 1590 (0.46%)3 0 (0%)2 324 (1.30%) 0 (0%)
Apolipoprotein A1 g/L 118 (0.03%)3 732 (0.21%)2 25 (0.10%) 57 (0.23%)
Alpha-2 macroglobulin g/L 419 (0.12%)2 427 (0.12%)3 54 (0.22%) 24 (0.10%)
GGT IU/L 0 (0%) 78 (0.02%)3 0 (0%) 8 (0.03%)
Total Bilirubin, μmol/L 0 (0%) 6 (0.001%)3 0 (0%) 0 (0%)
  1. 1Defined as a change > 0.30 in Fibrotest (at least 1.5 fibrosis METAVIR stage) when switching to the median value of the given parameter. Overall at least one parameter out of limits with significant impact was observed in 3349 cases (0.97%).
  2. 2 Risk of false negative
  3. 3 Risk of false positive